Tohoku's liquid-metal particle clears mouse TNBC tumors by stripping the Tregs first

Five times better tumor accumulation is a ratio, and the announcement prints no denominator ^[8][21]. That gap is the one that matters. The selectivity argument in this design is geographic: an anti-CD25 antibody riding on the particle surface kills the regulatory T cells it meets ^[9], so the fraction of injected dose that actually sits in the tumor decides whether "intratumoral" describes the biology or only the intent. Five times better than a conventional carrier is perfectly consistent with a small number becoming a slightly less small number.

Then there is the light. The core is a gallium-based liquid metal with reported photothermal conversion above 54%, and near-infrared irradiation takes the tumor to 58 C inside five minutes, which is what produces the immunogenic cell death and the antigen release ^[7][10]. The STING agonist DMX is also released on laser command, and that arm is what matures dendritic cells and drives interferon-beta ^[11]. So two of the three coordinated attacks do not happen in the dark; only Treg depletion is light-independent ^[12]. This is why the roadmap that names pancreatic and ovarian cancer as the next targets ^[15] also carries a line about NIR-II compatible formulations for deeper tumors ^[16]. Those are not parallel workstreams. The second gates the first, because an orthotopic mouse mammary tumor is close to the friendliest geometry a laser will ever be handed.

The survival figure needs reconciling. The paper, first-authored by Nina Sang in Advanced Science ^[6], reports complete tumor regression in every treated animal, lung metastases suppressed by more than 90%, and median survival extended beyond 70 days ^[13]. If all primary tumors cleared, a median survival number has to come from somewhere: either follow-up stopped around day 70, or animals died later, plausibly from the residual metastatic disease that "more than 90%" leaves behind ^[23]. The summary does not say which, and the difference is the difference between a cure model and a delay model.

What travels to other cancers is not the 100%. It is the immune readout: more than a 13-fold rise in CD3-positive T cells and an 11-fold rise in dendritic cells inside treated tumors ^[14]. That is the evidence that a cold tumor was made warm, and warmth is the property the group wants to reproduce in pancreas and ovary, where Tregs play the same suppressive role ^[15]. It is also the whole point of the exercise. Triple-negative disease is 15% to 20% of breast cancer, without the receptors that make other subtypes druggable ^[1][2], and immunotherapy currently helps fewer than one in five of these patients, largely because Tregs are present to stop it ^[3]. That leaves more than 80% getting nothing from checkpoint-era medicine ^[4]. Eijiro Miyako's own framing is modest about what has been shown: three approaches in one particle, and a next step of finding out whether it is safe and effective in other solid tumors ^[18].